Lenalidomid Sandoz (Lenalidomide)

Lenalidomid Sandoz is used in hematologic malignancies and related bone‑marrow disorders, targeting abnormal plasma‑cell and lymphoid proliferation through immunomodulation.

• Multiple myeloma: improves progression‑free survival and overall response when combined with dexamethasone or other agents.
• Myelodysplastic syndromes with del(5q): induces transfusion independence and cytogenetic remission.
• Mantle cell lymphoma: provides disease control as part of combination therapy in relapsed or refractory cases.

• Lenalidomide binds to the cereblon component of the CRL4‑CRBN E3 ubiquitin ligase complex, altering its substrate specificity. This triggers ubiquitination and proteasomal degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), reducing survival signals in malignant cells. The drug also modulates cytokine production, enhances natural‑killer cell activity, and exerts anti‑angiogenic effects, collectively contributing to its antineoplastic activity.

Lenalidomid Sandoz may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Neutropenia: reduced neutrophil count, increasing infection risk.
• Thrombocytopenia: low platelet levels, may cause bleeding.
• Anemia: decreased red blood cell count, leading to fatigue.
• Fatigue: general feeling of tiredness.
• Diarrhea: loose stools, may require hydration.
• Rash: mild skin irritation or erythema.

Serious or Rare Side Effects

• Venous thromboembolism: blood clots in deep veins or lungs.
• Severe neutropenia: markedly low neutrophils with fever.
• Secondary primary malignancies: emergence of new cancers.
• Hepatotoxicity: elevated liver enzymes or liver injury.
• Embryo‑fetal toxicity: potential harm to developing fetus.
• Stevens‑Johnson syndrome: severe skin and mucosal reaction.

Before prescribing Lenalidomid Sandoz, clinicians should consider several safety and handling precautions.

• Baseline blood counts: obtain CBC to assess neutrophils, platelets and hemoglobin.
• Thrombo‑prophylaxis: evaluate need for anticoagulation in patients at risk of clotting.
• Renal function: adjust monitoring in patients with impaired kidney function.
• Hepatic function: monitor liver enzymes during therapy.
• Pregnancy risk: avoid use in pregnancy; ensure effective contraception for women of childbearing potential.
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Lenalidomid Sandoz can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce lenalidomide exposure.
• Anticoagulants (e.g., warfarin, direct oral anticoagulants): increased risk of bleeding when combined with thrombocytopenia.

Moderate Interactions (Monitor Closely)

• Immunosuppressants (e.g., cyclosporine, tacrolimus): may enhance immunosuppressive effects.
• Vaccines: live attenuated vaccines should be avoided due to altered immune response.
• NSAIDs: may increase risk of renal impairment when combined with lenalidomide‑related dehydration.